1 BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma
MEKTOVI in combination with encorafenib demonstrated a statistically significant improvement in PFS compared to vemurafenib. Efficacy results are summarized in Table 7 and Figure 1.
